Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 1, January, p. 115–121

doi: 10.17219/acem/112058

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson’s disease

Justyna Chojdak-Łukasiewicz1,A,B,D, Małgorzata Małodobra-Mazur2,C, Anna Zimny3,C, Leszek Noga4,C, Bogusław Paradowski1,A,F

1 Department of Neurology, Wroclaw Medical University, Poland

2 Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Poland

3 Department of General Radiology, Interventional Radiology and Neuroradiology, Wroclaw Medical University, Poland

4 Department of Pathophysiology, Wroclaw Medical University, Poland

Abstract

Background. Parkinson’s disease (PD) is a progressive neurodegenerative disorder with a characteristic clinical picture. Apart from classical movement disorders, a significant role is also played by non-motor symptoms, in particular cognitive impairments, which have a significant impact on the quality of life of the patients. Tau protein and amyloid beta are well-known non-specific biomarkers in Alzheimer’s disease (AD).
Objectives. The study assessed the practical value of determining tau protein and amyloid beta (Aβ42) in the blood serum of patients with PD and their relationship with cognitive impairments, radiographic image and the used dose of L-DOPA.
Material and Methods. The neuropsychological assessment was carried for 64 patients with PD. The levels of amyloid beta 1-42 (Aβ42) and tau proteins in serum were also measured.
Results. The Aβ42 level in the serum was statistically higher in patients with longer duration of the disease (p < 0.05) and those who were taking a higher dose of L-DOPA (p < 0.05). The average level of tau protein in the serum was slightly lower in the study groups than in the control group and showed no statistical significance. No correlation was found between the levels of tau protein and Aβ42 and the results of neuropsychological tests. Tau protein correlated with hippocampal atrophy (p < 0.05).
Conclusion. Serum levels of Aβ42 and tau protein in PD may be a useful marker for the assessment of cognitive impairments. The role of L-DOPA in the process of dementia in PD remains unclear.

Key words

Parkinson’s disease, dementia, amyloid β-protein, tau protein

References (33)

  1. Lees A, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373(9680):2055–2066.
  2. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for non­motor manifestations of Parkinson’s disease. Mov Disord. 2015;30(11):1490–1504.
  3. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. J Neurol Sci. 2010;289(1–2):18–22.
  4. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):99–103.
  5. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98–106.
  6. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord. 2004;19(9):1020–1028.
  7. Torisson G, van Westen D, Stavenow L, et al. Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients. BMC Geriatrics. 2015;15(1):65. doi:10.1186/s12877-015-0066-4
  8. Overdorp EJ, Kessels RP, Claassen JA, Oosterman JM. Cognitive impairments associated with medial temporal atrophy and white matter hyperintensities: An MRI study in memory clinic patients. Front Aging Neurosci. 2014;6:98.
  9. Montine TH, Shi M, Quinn JF, et al. CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25(15):2682–2685.
  10. Alves G, Lange J, Blennow K, et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784–1790.
  11. Shi M, Zhang J. CSF α-synuclein, tau, and amyloid β in Parkinson’s disease. Lancet Neurol. 2011;10(8):681–683.
  12. Leverenz JB, Watson S, Shofer J. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(1):61–64.
  13. Siderowf A, Xie SH, Hurtig H, et al. CSF amyloid β1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–1061.
  14. Přikrylová Vranová H, Mareš J, Hluštík P, et al. Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson’s disease. J Neural Transm (Vienna). 2012;119(3):353–362.
  15. Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontol. 2010;45(1):5–14.
  16. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer’s disease: Current concepts. Mol Neurodegener. 2013;8:20. doi:10.1186/1750-1326-8-20
  17. Donohue MC, Moghadam SH, Roe AD, et al. Longitudinal plasma amyloid beta in Alzheimer’s disease clinical trials. Alzheimers Dement. 2015;11(9):1069–1079.
  18. Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements: A desired but elusive Alzheimer’s disease biomarker. Alzheimers Res Ther. 2013;5(2):8. doi:10.1186/alzrt162
  19. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med. 1996;2(8):864–870.
  20. Blasko I, Kemmler G, Krampla W, et al. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging. 2005;26(8):1135–1143.
  21. Fukumoto H, Tennis M, Locascio JJ. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60(7):958–964.
  22. Chouraki V, Beiser A, Younkin L, et al. Plasma amyloid-β and risk of Alzheimer’s disease in the Framingham Heart Study. Alzheimers Dement. 2015;11(3):249–257.
  23. Lopez OL, Kuller LH, Mehta PD, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 2008;70(19):1664–1671.
  24. Hansson O, Stomrud E, Vanmechelen E, et al. Evaluation of plasma Aβ as predictor of Alzheimer’s disease in older individuals without dementia: A population-based study. J Alzheimers Dis. 2012;28(1):231–238.
  25. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol. 2006;5(8):655–660.
  26. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol. 2012;69(7):824–831.
  27. Nascimento KK, Silva KP, Malloy-Diniz LF, Butters MA, Diniz BS. Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis. J Psychiatr Res. 2015;69:35–41.
  28. Liu YH, Xiang Y, Wang YR, et al. Association between serum amyloid-beta and renal functions: Implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol. 2015;52(1):115–119.
  29. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology. 2014;82(12):1051–1057.
  30. Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): A blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett. 2001;300(2):95–98.
  31. Georgieff IS, Liem RK, Couchie D, Mavilia C, Nunez J, Shelanski ML. Expression of high molecular weight tau in the central and peripheral nervous systems. J Cell Sci. 1993;105(Pt 3):729–737.
  32. Hattori H, Matsumoto M, Iwai K, et al. The tau protein of oral epithelium increases in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2002;57(1):64–70.
  33. Ingelson M, Blomberg M, Benedikz E, et al. Tau immunoreactivity detected in human plasma but no obvious increase in dementia. Dement Geriatr Cogn Disord. 1999;10(6):442–445.